D
ADC Therapeutics SA ADCT
$3.65 -$0.31-7.72% NYSE
Recommendation
Prev Close
$3.95
Volume
1,690,349
Avg Vol (90D)
962,846
Market Cap
$489.31M
Dividend & Yield
--
52-Week Range
$1.05 - $4.80
P/E (TTM)
--
EPS (TTM)
-$1.45
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
RBC Capital Sticks to Its Buy Rating for ADC Therapeutics (ADCT)
12/4/2025 - TipRanks Financial Blog
ADC Therapeutics (NYSE:ADCT) Trading Up 6.5% - Should You Buy?
12/3/2025 - MarketBeat
Why Is ADC Therapeutics Plunging Today
12/3/2025 - Benzinga
ADC Therapeutics SA (ADCT, $4.6) price may drop as it broke higher Bollinger Band on Dec 02, 2025
12/3/2025 - Tickeron - Stocks
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL - Slideshow
12/3/2025 - SeekingAlpha
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript
12/3/2025 - SeekingAlpha
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript
12/3/2025 - Seeking Alpha: Transcripts
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma
12/3/2025 - TipRanks Financial Blog
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma
12/3/2025 - The Fly
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
12/3/2025 - PR Newswire
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
12/2/2025 - GuruFocus
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
12/2/2025 - PR Newswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
12/1/2025 - GuruFocus
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
12/1/2025 - PR Newswire
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
12/1/2025 - Zacks Investment Research
ADC Therapeutics SA (ADCT, $4.39) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 25, 2025
11/26/2025 - Tickeron - Stocks
ADC Therapeutics SA (ADCT, $4.37) price may drop as it broke higher Bollinger Band on Nov 24, 2025
11/25/2025 - Tickeron - Stocks
ADC Therapeutics SA (ADCT, $3.99) entered Downtrend as Momentum indicator drops below 0 level on Nov 20, 2025
11/21/2025 - Tickeron - Stocks
ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know
11/18/2025 - Zacks Investment Research
Wall Street Zen Upgrades ADC Therapeutics (NYSE:ADCT) to "Hold"
11/16/2025 - MarketBeat
FY2025 EPS Estimates for ADCT Increased by Cantor Fitzgerald
11/14/2025 - MarketBeat
ADC Therapeutics SA (ADCT, $4.21) Stochastic Oscillator left the oversold zone on November 10, 2025
11/11/2025 - Tickeron - Stocks
ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Expectations By $0.10 EPS
11/11/2025 - MarketBeat
ADC Therapeutics Reports Q3 2025 Financial Results
11/11/2025 - TipRanks Financial Blog
ADC Therapeutics Q3 2025 Earnings Call Highlights
11/11/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$75.21M
EBITDA (TTM)
-$121.50M
EBIT (TTM)
-$122.55M
Net Income (TTM)
-$166.94M
Balance Sheet
Total Assets (Q)
$289.76M
Total Debt (Q)
$457.44M
Total Liabilities (Q)
$527.94M
Book Value Per Share (Q)
-$2.11
Cash Flow
Cash from Operations (TTM)
-$131.90M
Cash from Investing (TTM)
-$354.00K
Cash from Financing (TTM)
$92.74M
Net Change in Cash (TTM)
-$39.53M
Filings
Filing Date
Monday, November 10, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Loading...
Beta
1.98
7-Day Total Return
-16.48%
30-Day Total Return
-10.32%
60-Day Total Return
13.00%
90-Day Total Return
26.30%
Year to Date Total Return
82.50%
1-Year Total Return
76.33%
2-Year Total Return
228.83%
3-Year Total Return
3.99%
5-Year Total Return
-89.82%
52-week Low
Apr 07, 2025 - $1.05
52-week High
Oct 30, 2025 - $4.80
Valuation
Market Cap
$489.31M - Small Cap
Enterprise Value
$712.01M
Price/Sales (TTM)
7.17
Price/Book (Q)
-1.87
Dividends and Shares
Shares Outstanding
136.45
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.adctherapeutics.com
Phone Number
41 21 653 02 00
Address
BiopOle
Epalinges, 1066
Country
Switzerland
Year Founded
2011
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship... more
NYSE 12/04/2025 2:52PM Eastern Quotes delayed